周三盘中，部分生物技术股上扬。 药捷安康-B 拉升涨超17%， 据药捷安康官微消息，核心产品替恩戈替尼在美国开展的针对胆管癌的探索性临床2期结果在《柳叶刀，胃肠病和肝病学》(影响因子38.6)上发表。昭衍新药 涨超9%， 轩竹生物-B 涨超5%， 银诺医药－Ｂ 涨超3%。
周三盘中，部分生物技术股上扬。 药捷安康-B 拉升涨超17%， 据药捷安康官微消息，核心产品替恩戈替尼在美国开展的针对胆管癌的探索性临床2期结果在《柳叶刀，胃肠病和肝病学》(影响因子38.6)上发表。昭衍新药 涨超9%， 轩竹生物-B 涨超5%， 银诺医药－Ｂ 涨超3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
